{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.71","upperLimit":"5.32","value":"4.4"},{"groupId":"OG001","lowerLimit":"3.32","upperLimit":"4.86","value":"4.11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"119"}],"units":"Participants"}],"description":"Duration from start of treatment to first evidence of disease progression as assessed by the investigator. See definitions of response and progression in ORR and PFS outcomes.","dispersionType":"95% Confidence Interval","groups":[{"description":"Melphalan flufenamide (melflufen) 40 mg Day 1 and dexamethasone 40 mg (reduced dose for patients 75 years or older) on Days 1, 8, 15 and 22 of each 28-day cycle.\n\nMelphalan flufenamide (Melflufen)\n\nDexamethasone","id":"OG000","title":"Melphalan Flufenamide (Melflufen) + Dexamethasone: Full Analysis Set"},{"description":"Triple class refractory population defined as refractory to or intolerant of at least one immunomodulatory drug, at least one proteasome inhibitor, and at least one anti-CD38 monoclonal antibody","id":"OG001","title":"Melphalan Flufenamide (Melflufen) + Dexamethasone: Patients With Triple Class Refractory Disease"}],"paramType":"MEDIAN","populationDescription":"This outcome measure was prespecified to be analyzed/reported for the Mel + Dex: FAS Arm/Group and Mel + Dex: Patients With TCR Disease.\n\nThis outcome measure was analyzed/reported for patients in the full analysis set as well as in the sub-group of patients with triple class refractory disease.\n\nThis outcome measure was not analyzed/reported separately for the sub-group of patients with Extramedullary Disease. No data available to report for EMD patients.","reportingStatus":"POSTED","timeFrame":"From start of treatment to first evidence of disease progression or date of death from any cause, whichever came first. Longest time to progression recorded was 37.2 months at study end.","title":"Time to Progression","type":"SECONDARY","unitOfMeasure":"months"}